Sanofi Capital

Sanofi is a global biopharmaceutical leader headquartered in Paris, France, focused on transforming scientific innovation into healthcare solutions. The company operates through core business units including Specialty Care, Vaccines, and General Medicines, with a significant strategic pivot toward immunology and inflammation. Sanofi's portfolio is anchored by the blockbuster monoclonal antibody Dupixent, which is approved for multiple type 2 inflammatory diseases. Through key acquisitions such as Ablynx and Translate Bio, the company has integrated advanced Nanobody and mRNA platforms into its R&D engine. Sanofi maintains a robust clinical pipeline targeting high-unmet-need areas in oncology, neurology, and rare diseases while remaining a world leader in vaccine development.